ABVC BioPharma (NASDAQ:ABVC) Stock Price Up 2.5% – Time to Buy?

ABVC BioPharma, Inc. (NASDAQ:ABVC) was up 2.5% during mid-day trading on Tuesday . The stock traded as high as $1.2598 and last traded at $1.23. 41,860 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 198,254 shares. The stock had previously closed at $1.20.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

ABVC BioPharma Trading Up 2.5%

The company has a market cap of $31.98 million, a price-to-earnings ratio of -3.07 and a beta of 0.54. The stock has a 50 day moving average price of $1.37 and a two-hundred day moving average price of $1.47.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings data on Monday, May 18th. The company reported ($0.06) EPS for the quarter.

Institutional Trading of ABVC BioPharma

A number of institutional investors and hedge funds have recently modified their holdings of ABVC. Geode Capital Management LLC boosted its stake in ABVC BioPharma by 7.7% during the 4th quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock worth $431,000 after acquiring an additional 14,553 shares during the last quarter. Millennium Management LLC bought a new stake in ABVC BioPharma in the third quarter valued at approximately $60,000. Finally, Citadel Advisors LLC bought a new stake in ABVC BioPharma in the third quarter valued at approximately $48,000. 11.38% of the stock is owned by institutional investors.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.